Entering text into the input field will update the search result below

Omeros launches Omidria in U.S.

Apr. 02, 2015 12:16 PM ETOmeros Corporation (OMER) StockBy: Douglas W. House, SA News Editor
  • Omeros (NASDAQ:OMER +0.9%) announces that Omidria (phenylephrine and ketorolac injection) is now commercially available throughout the U.S. It is indicated for administration during cataract surgery and other intraocular lens replacement procedures to prevent intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.
  • The nationwide launch follows a two-month controlled launch which allowed the company to refine its commercial processes.
  • The FDA approved Omidria in June of last year. The European Medicines Agency's review is ongoing.

Recommended For You

More Trending News

About OMER Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
OMER--
Omeros Corporation